News

HIV prevention is entering a new phase with the rise of innovative medications like the twice-yearly injectable lenacapavir.
Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
LONDON -- The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, ...
The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...
Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...
In 2024, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...
Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.
Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...
DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...